OrganiGram Holdings Inc. (OGI.TO)
CAD 2.1
(-7.89%)
CAD 2.1
(-7.89%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 35.07 Million CAD | 11.1% |
| 2022 | 31.56 Million CAD | 211.16% |
| 2021 | -28.39 Million CAD | 49.73% |
| 2020 | -56.49 Million CAD | -216.55% |
| 2019 | 48.46 Million CAD | -7.68% |
| 2018 | 52.49 Million CAD | 1778.85% |
| 2017 | -3.12 Million CAD | -158.84% |
| 2016 | 5.31 Million CAD | 300.72% |
| 2015 | 1.32 Million CAD | 582.42% |
| 2014 | -274.9 Thousand CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -908 Thousand CAD | -113.55% |
| 2024 Q3 | -805 Thousand CAD | 1642.73% |
| 2024 Q1 | 6.7 Million CAD | 152.57% |
| 2023 Q2 | 9.8 Million CAD | -58.96% |
| 2023 Q3 | -4.69 Million CAD | -147.92% |
| 2023 Q4 | -12.74 Million CAD | -171.36% |
| 2023 Q1 | 23.88 Million CAD | 67.64% |
| 2023 FY | -33.8 Million CAD | -207.09% |
| 2022 Q4 | 14.24 Million CAD | 86.44% |
| 2022 Q3 | 7.64 Million CAD | -15.73% |
| 2022 Q2 | 9.06 Million CAD | 1386.72% |
| 2022 FY | 31.56 Million CAD | 211.16% |
| 2022 Q1 | 610 Thousand CAD | -81.8% |
| 2021 Q2 | -17.19 Million CAD | -3.12% |
| 2021 Q3 | 2.11 Million CAD | 112.32% |
| 2021 Q4 | 3.35 Million CAD | 58.14% |
| 2021 Q1 | -16.67 Million CAD | 42.02% |
| 2021 FY | -28.39 Million CAD | 49.73% |
| 2020 Q3 | -50.21 Million CAD | -544.86% |
| 2020 Q4 | -28.75 Million CAD | 42.74% |
| 2020 FY | -56.49 Million CAD | -216.55% |
| 2020 Q1 | 11.19 Million CAD | 201.24% |
| 2020 Q2 | 11.28 Million CAD | 0.84% |
| 2019 Q4 | -11.05 Million CAD | -6077.09% |
| 2019 Q1 | 51.74 Million CAD | 60.52% |
| 2019 Q3 | -179 Thousand CAD | -102.25% |
| 2019 FY | 48.46 Million CAD | -7.68% |
| 2019 Q2 | 7.95 Million CAD | -84.62% |
| 2018 Q3 | 12.12 Million CAD | 85.83% |
| 2018 FY | 52.49 Million CAD | 1778.85% |
| 2018 Q4 | 32.23 Million CAD | 165.96% |
| 2018 Q2 | 6.52 Million CAD | 303.17% |
| 2018 Q1 | 1.61 Million CAD | 91.51% |
| 2017 Q1 | 762.89 Thousand CAD | -62.02% |
| 2017 Q2 | -3.97 Million CAD | -621.35% |
| 2017 Q3 | -757.41 Thousand CAD | 80.96% |
| 2017 Q4 | 844.78 Thousand CAD | 211.53% |
| 2017 FY | -3.12 Million CAD | -158.84% |
| 2016 Q3 | 1.58 Million CAD | 46.12% |
| 2016 Q4 | 2 Million CAD | 26.98% |
| 2016 FY | 5.31 Million CAD | 300.72% |
| 2016 Q1 | 640.83 Thousand CAD | -11.02% |
| 2016 Q2 | 1.08 Million CAD | 68.94% |
| 2015 Q2 | 125.1 Thousand CAD | 173.2% |
| 2015 Q1 | -170.91 Thousand CAD | 37.59% |
| 2015 Q4 | 720.16 Thousand CAD | 10.48% |
| 2015 FY | 1.32 Million CAD | 582.42% |
| 2015 Q3 | 651.82 Thousand CAD | 421.02% |
| 2014 Q4 | -273.85 Thousand CAD | -25956.52% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | -274.9 Thousand CAD | 0.0% |
| 2014 Q3 | -1051.00 CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Aurora Cannabis Inc. | 131.46 Million CAD | 73.32% |
| Avicanna Inc. | 6.65 Million CAD | -426.729% |
| Avant Brands Inc. | 12.43 Million CAD | -182.121% |
| Cardiol Therapeutics Inc. | -248.35 Thousand CAD | 14222.217% |
| Crescita Therapeutics Inc. | 10.36 Million CAD | -238.414% |
| Knight Therapeutics Inc. | 152.65 Million CAD | 77.024% |
| MediPharm Labs Corp. | 5.85 Million CAD | -499.031% |
| Canopy Growth Corporation | 80.88 Million CAD | 56.637% |
| Willow Biosciences Inc. | -659 Thousand CAD | 5422.19% |
| Auxly Cannabis Group Inc. | 21.27 Million CAD | -64.841% |